To provide the information your oncologist is not telling you or doesn't have the time to!
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
This is a new clinical trial using Tebentafusp alone or in combination with Pembrolizumab is now open and actively enrolling at the Orlando Health Cancer Institute for patients dealing with Metastatic Cutaneous Melanoma. Tebentafusp is currently FDA approved for all patients with Metastatic Uveal Melanoma. Detailed information can be found here at clinicaltrials.gov and NEJM …
Article written by one of our Melanoma/Sarcoma Clinical Trial Coordinators Chloe Caldwell to a target audience of healthcare providers regarding a new ongoing protocol for patients dealing with GIST open globally and at the Orlando Health Cancer Institute. All information posted here is publicly available here. Gastrointestinal Stromal Tumors (GIST) constitute a category of soft …
Great review article published in the JCO here by Daniel Olson et al. summarizing adoptive cellular therapy for solid tumors and where we are today. I am very excited about solid tumor cellular therapy as we are currently enrolling into solid tumor trials specifically for TIL, PD1 knockout TIL, Neoantigen Selective TIL and TCR MAGE4+ …
ASCO 2023 was an incredible conference and I had completely enjoyed the networking, presentations, and evening meetings. Here are two melanoma clinical trials that we had also participated in enrollment at the Orlando Health Cancer Institute. It is incredibly exciting to see patients do better with improved responses as well as improved odds of not …
ASCO 2023 was a ton of fun and lot of learning. In the coming weeks, I’ll share select abstracts that I thought were most important. This article discusses data from a groundbreaking PROSPECT trial which was presented as a Plenary topic at Chicago and published in NEJM last week. Ultimately, this creates more treatment options …
Replaying this post as a reminder that this study is enrolling at multiple sites globally. More detailed information can also be seen here at clinicaltrials.gov as well as the sponsor Iovance. All information and data stated in this article are available publicly through online resources that I’ve also linked below for reference. This new trial …
mRNA technology has revolutionized the world of medicine. Known for its role in the creation of COVID-19 vaccines, mRNA has been lauded as a game-changer in the fight against infectious diseases. But mRNA’s impact extends far beyond pandemic control. It’s now making waves in another critical area of healthcare: cancer treatment and prevention. mRNA stands …
I am really excited about this new protocol specifically for patients with MAGE4+ HLA restricted SPEAR TILs for Metastatic Melanoma, Non-small Cell Lung Cancer, Head Neck cancer, Ovarian, Endometrial, and Urothelial cancers. The Gastric and Esophageal Cancer cohorts are closed. The social media material seen here was approved both the sponsor and IRB. Please contact …
My very first mentor was Dr Larry Kvols who I trained under at the Moffitt Cancer Center during my internal medicine residency. He would tell some good stories on some of the first patients he treated back in the day with a drug no one has ever heard using “octreotide” which today is the main …
Colon cancer is the third most common cancer worldwide, affecting millions of individuals every year. Currently, the treatment paradigm for resected stage 2 and 3 colon cancer patients typically involves surgery followed by adjuvant chemotherapy to reduce the risk of cancer recurrence. However, the prognosis for these patients varies significantly, with some experiencing a complete …